Latest Breaking News On - Coheru chief medical - Page 1 : comparemela.com

Coherus Presents Preliminary Results from Phase I Dose

CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective.

United statesMccormick placeRosh diasJodi sieversCoherus biosciencesJami taylorCorporate communicationsAbbvie incExchange commissionExchange commission onAmgen incCoherus biosciences incCoheru chief medicalPreliminary resultsDose escalation studyAdvanced solid

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesMccormick placeRosh diasJodi sieversCoherus biosciencesJami taylorAbbvie incCorporate communicationsExchange commission onAmerican society of clinical oncologyExchange commissionAmgen incCoherus biosciences incPresents preliminary resultsPhasei dose escalation studyClinical oncology

Coherus (CHRS) Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody

Coherus (CHRS) Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoWest hallDaneng liRosh diasCoherus biosciences incCity of hope comprehensive cancer centerLiver cancer collaborative programDepartment of medical oncology therapeutics researchCancers symposiumMoscone westAssociate professorMedical oncologyTherapeutics researchHope comprehensive cancerCoheru chief medical

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesWest hallSan franciscoJodi sieversJami taylorDaneng liRosh diasCoherus biosciencesMike beyerRed house communicationsCoherus biosciences incLiver cancer collaborative programExchange commissionVp corporate communicationsCity of hope comprehensive cancer centerDepartment of medical oncology therapeutics research

Junshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

- Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with toripalimab plus chemotherapy significantly prolongs survival in patients with advanced NPC - SHANGHAI, China

United statesDennis riedlPatricia keeganJunshi bioscienceJunshi topalliance biosciencesMarek ciszewskiRosh diasJodi sieversJunshi biosciencesCoherus biosciencesZhi liExchange commission onIr teamCoherus biosciences incExchange commissionVp corporate communications